Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
253 hedge funds and large institutions have $4.1B invested in Global Blood Therapeutics, Inc. in 2020 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 76 increasing their positions, 81 reducing their positions, and 26 closing their positions.
135% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 26
23% more capital invested
Capital invested by funds: $3.33B → $4.1B (+$773M)
15% more funds holding
Funds holding: 220 → 253 (+33)
6% more call options, than puts
Call options by funds: $52.8M | Put options by funds: $50M
6% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 81
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53M |
| 2 |
TCM
TimesSquare Capital Management
New York
|
+$49.1M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$37.2M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$30.9M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$80.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$42.4M |
| 3 |
RI
RTW Investments
New York
|
-$36.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.8M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$28.4M |
GBT Hedge Fund Activity: Q2 2020 in Review
253 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q2 2020, worth a combined $4.1B — up 23% from $3.33B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new GBT positions and 26 closed out — a net gain of 35 holders — while 76 added to existing stakes and 81 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53M. The largest seller was BlackRock, cutting an estimated $80.7M.
- 253 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q2 2020, up from 220 in Q1 2020.
- Funds reported $4.1B of Global Blood Therapeutics, Inc. stock for Q2 2020, up 23% quarter-over-quarter.
- 61 funds opened new Global Blood Therapeutics, Inc. positions in Q2 2020 and 26 closed out, a net change of +35 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q2 2020 was Fidelity Investments, an estimated $53M added.
- The largest Global Blood Therapeutics, Inc. seller in Q2 2020 was BlackRock, an estimated $80.7M sold.
Based on aggregated 13F filings for Q2 2020.